Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,003 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma

NCT00088205

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Woolloongabba, Queensland, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Parkville, Victoria, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Prahran, Victoria, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Wodonga, Victoria, Australia
View all 17 locations
View Trial Details
Completed

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

NCT01388335

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bordeaux, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Dijon, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Lille, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Paris, France
View Trial Details
Completed

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

NCT01217229

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • Northwestern University, The Robert H Lurie Comprehensive Cancer Center Chicago, Illinois, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details
Completed

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

NCT01854567

Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Hematologic Diseases, +17 more
Locations
  • University of Miami Health System Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

NCT02812875

Conditions
Adenoma, Advanced Solid Tumors or Lymphomas, Hemic and Lymphatic Diseases, +10 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Sarah Cannon Research Institute Sarasota, Florida, United States
  • Northwestern University Chicago, Illinois, United States
View all 20 locations
View Trial Details
Completed

Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

NCT00824265

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • Novartis Investigative Site Boca Raton, Florida, United States
  • Novartis Investigative Site Chicago, Illinois, United States
  • Novartis Investigative Site Clinton, Maryland, United States
  • Novartis Investigative Site Kansas City, Missouri, United States
View all 135 locations
View Trial Details
Completed

LAM Pilot Study With Imatinib Mesylate

NCT03131999

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Columbia University New York, United States
  • Medical University of South Carolina Charleston, South Carolina, United States
View Trial Details

Related conditions